BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000139:chemically induced; D003561:Cytarabine / Q000009:adverse effects; D005069:Evaluation Studies as Topic; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D008875:Middle Aged; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014508:Urea / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D003561:Cytarabine; D014508:Urea; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase